Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

Publisher： Karger

E-ISSN： 1660-3818|38|1|33-42

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.38, Iss.1, 2011-01, pp. : 33-42

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation

By  

TRANSFUSION, Vol. 55, Iss. 12, 2015-12 ,pp. : 2983-3000

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of Various Blood Bank Filtres for Leukocyte Depletion of Red Blood Cell Concentrates

By  

Transfusion Medicine and Hemotherapy, Vol. 25, Iss. 5, 1998-10 ,pp. : 312-316

Karger

Access to resources Recommend Favorite

Model Calculations to Quantify Clinical and Economic Effects of Pathogen Inactivation in Platelet Concentrates

By  

Oncology Research and Treatment, Vol. 36, Iss. 1-2, 2013-01 ,pp. : 53-59

Karger

Access to resources Recommend Favorite

Pathogen Inactivation Technologies for Cellular Blood Components: an Update

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 4, 2014-07 ,pp. : 309-325

Karger

Access to resources Recommend Favorite

Validation of a Pneumatic Post between Two Hospitals for the Transport of Red Cell Concentrates and Blood Samples

By  

Transfusion Medicine and Hemotherapy, Vol. 30, Iss. 6, 2003-12 ,pp. : 287-288

Karger

Access to resources Recommend Favorite